Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin effect on abdominal fat layers in type 2 diabetes
2019-000979-16Phase 4Completed
- Sponsor
- CPEN
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dapagliflozin in type 2 diabetes mellitus (T2DM) and Abdominal adiposity (ABCD) (2 arms), sponsored by CPEN. Primary endpoint: Change in omental fat layer thickness. Started Jun 2019; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)Abdominal adiposity (ABCD)
Beyond the preview
Go deeper on 2019-000979-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000979-16.